德勤:今年GenAI為大部分企業軟件產品重要組成部分
德勤發表《2024科技、傳媒和電信行業預測》報告指,GenAI今年將成為幾乎所有企業軟件產品的重要組成部分。軟件供應商和資訊科技部門很可能會為GenAI定價。報告預測,GenAI有可能在今年底前為企業軟件公司帶來100億美元的收入增長,對一個全新市場的發展元年來說是非凡的里程碑,但由於預計收入將主要出現在下半年而有可能低於一些市場預期。
德勤中國科技、傳媒和電信行業主管合夥人程中表示,GenAI已成為企業創新的基石,其發展速度超乎想像,並將推動全球專用芯片市場規模在2024年達到500億美元以上。在此背景下,行業領導者需密切關注監管動態,包括去年8月中內地推行的生成式人工智能服務管理暫行辦法》,同時利用沙盒進行創新實驗,充分釋放GenAI的力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.